Synthesis, structural characterization and biological study of new organotin(IV), silver(I) and antimony(III) complexes with thioamides.

An overview of our work on the synthesis and biological activity of a series of tin(IV), silver(I) and antimony(III) complexes with thioamides is reported. Organotin(IV) complexes of formulae (n-Bu)2Sn(MBZT)2 (1), Me2Sn(CMBZT)(2) (2), {(Ph3Sn)2(MNA) (Me2CO)} (3), Ph3Sn(MBZT) (4), Ph3Sn(MBZO) (5), Ph3Sn(CMBZT) (6), Ph2Sn(CMBZT)2 (7) and (n-Bu)2Sn(CMBZT)2 (8), Me2Sn(PMT)2 (9), (n-Bu)2Sn(PMT)2 (10), Ph2Sn(PMT)2 (11), Ph3Sn(PMT) (12) {where MBZT=2-mercapto-benzothiazole, CMBZT=5-chloro-2-mercapto-benzothiazole, H2MNA=2-mercapto-nicotinic acid, MBZO=2-mercapto-benzoxazole and PMTH=2-mercapto-pyrimidine} were characterized by spectroscopic (NMR, IR, Mossbauer, etc.) and X-ray diffraction techniques and their influence on the peroxidation of oleic acid was studied. They were found to inhibit strongly the peroxidation of linoleic acid by the enzyme lipoxygenase. In addition, organotin(IV) complexes were found to exhibit stronger cytotoxic activity in vitro, against leiomyosarcoma cells, than cisplatin. The antiproliferative activity of the organotin complexes studied, against leiomyosarcoma cells follow the same order of LOX activity inhibition. This is, 3>>12>7>6 approximately 8 approximately 10>5 approximately 4>>2>9. Thus, among organotin(IV)-CMBZT complexes, 7 exhibits higher activity than the others and this is explained by a free radical mechanism, as it is revealed by an EPR study. The results are compared with the corresponding ones found for the silver(I) complexes of formulae complexes {[Ag6(mu3-HMNA)4(mu3-MNA)2](2-).[(Et(3)NH)+]2.(DMSO)2.(H2O)} (13), {[Ag4Cl4(mu3-STHPMH2)4]n} (14), {[Ag6(mu2-Br)6(mu2-STHPMH2)4(mu3-STHPMH2)2]n} (15), {[Ag4(mu2STHPMH2)6](NO3)4}(n) (16), {[AgCl(TPTP)]4} (17), [AgX(TPTP)3] with X=Cl (18), Br (19), I (20) (where STHPMH2=2-mercapto-3,4,5,6-tetrahydro-pyrimidine, TPTP=tri(p-toly)phosphine) and those of antimony(III) complexes {[SbCl2(MBZIM)4](+).Cl(-).2H2O.(CH3OH)} (21), {[SbCl2(MBZIM)4]+.Cl(-).3H2O.(CH3CN)} (22), [SbCl3(MBZIM)2] (23), [SbCl3(EMBZIM)2] (24), [SbCl3(MTZD)2] (25), {[SbCl3(THPMT)2]} (26) and {[Sb(PMT)3].0.5(CH3OH)} (27) (where MBZIM is 2-mercapto-benzimidazole, EMBZIM=5-ethoxy-2-mercapto-benzimidazole and MTZD is 2-mercapto-thiazolidine), which they have characterized with similar techniques as in case of organotin(IV) complexes. Silver(I) and antimony(III) complexes were found to be cytotoxic against various cancer cell lines.

[1]  S. Skoulika,et al.  Synthesis, structural characterization, and biological studies of six- and five-coordinate organotin(IV) complexes with the thioamides 2-mercaptobenzothiazole, 5-chloro-2-mercaptobenzothiazole, and 2-mercaptobenzoxazole. , 2007, Inorganic chemistry.

[2]  J. Vicente,et al.  Complexes with S-Donor Ligands, 4. Mono- and Di-Homo- and -Hetero-Nuclear Gold(I), Silver(I), and Palladium(II) Complexes with 2-(Methylthio)pyridine, Pyridine-2(1H)-thione, and Benzoxazole-2(3H)-thione. Some Examples of the Use of Complexes as Ligands† , 1996 .

[3]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[4]  K. Jurkschat,et al.  Synthesis, structural characterization and in vitro cytotoxicity of organotin(IV) derivatives of heterocyclic thioamides, 2-mercaptobenzothiazole, 5-chloro-2-mercaptobenzothiazole, 3-methyl-2-mercaptobenzothiazole and 2-mercaptonicotinic acid. , 2003, Journal of inorganic biochemistry.

[5]  E. Tiekink.  Antimony and bismuth compounds in oncology. , 2002, Critical reviews in oncology/hematology.

[6]  J. Roberts,et al.  Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds , 1972, Nature.

[7]  J. Jordanov,et al.  Anti-tumour activity of heavy transition metal complexes against hepatoma cells. , 1975, Chemico-biological interactions.

[8]  M. Guo,et al.  Interactions of organometallic anticancer agents with nucleotides and DNA , 1999 .

[9]  M. Pariza,et al.  Newly recognized anticarcinogenic fatty acids: identification and quantification in natural and processed cheeses , 1989 .

[10]  T. Bakas,et al.  Interaction of Et2SnCl2 with 5'-IMP and 5'-GMP. , 1998, Journal of inorganic biochemistry.

[11]  H S Rosenkranz,et al.  Silver Sulfadiazine: Interaction with Isolated Deoxyribonucleic Acid , 1972, Antimicrobial Agents and Chemotherapy.

[12]  A. Michaelides,et al.  Synthesis, study and structural characterization of a new water soluble hexanuclear silver(I) cluster with the 2-mercapto-nicotinic acid with possible antiviral activity , 2003 .

[13]  K. Jurkschat,et al.  Communication: Synthesis of a Novel Triphenyltin(IV) Derivative of 2- Mercaptonicotinic Acid with Potent Cytotoxicity in vitro , 2003, Bioinorganic Chemistry and Applications.

[14]  N. Hadjiliadis,et al.  A New Silver(I) Aggregate Having an Octagonal Ag4S4 Core Where μ3‐S Bonding Interactions Lead to a Nanotube Assembly that Exhibits Quasiaromaticity , 2007 .

[15]  M. Xanthopoulou,et al.  Biological studies of new organotin(IV) complexes of thioamide ligands. , 2008, European journal of medicinal chemistry.

[16]  H. Schmidbaur,et al.  Assembly of the [CAu6]2⊕ Cluster with a Tailor‐made Diphosphane Spanning the Octahedral Edges , 1990 .

[17]  Edward R. T. Tiekink,et al.  Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine , 2005 .

[18]  H. Schmidbaur,et al.  Aufbau des [CAu6]2⊕-Clusters mit einem maßgeschneiderten, die Oktaederkanten überspannenden Diphosphan† , 1990 .

[19]  F. Huber,et al.  Organotin compounds and cancer chemotherapy , 1989 .

[20]  N. Hadjiliadis,et al.  Synthesis and characterization of new water stable antimony(III) complex with pyrimidine-2-thione and in vitro biological study , 2005 .

[21]  E. S. Raper.  Complexes of heterocyclic thione donors , 1985 .

[22]  W. Isaacs,et al.  Cyclooxygenases in cancer: progress and perspective. , 2004, Cancer letters.

[23]  Jan Balzarini,et al.  Synthesis, Characterization and in Vitro Study of the Cytostatic and Antiviral Activity of New Polymeric Silver(I) Complexes with Ribbon Structures Derived from the Conjugated Heterocyclic Thioamide 2-Mercapto-3,4,5,6-tetra- hydropyrimidine , 2004 .

[24]  P. Sadler,et al.  Medicinal Inorganic Chemistry , 1999 .

[25]  W. R. Porter,et al.  The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. , 1985, Drug metabolism reviews.

[26]  M. Gielen.  Review: Organotin compounds and their therapeutic potential: a report from the Organometallic Chemistry Department of the Free University of Brussels , 2002 .

[27]  J. Balzarini,et al.  Synthesis, structural characterization, and biological studies of new antimony(III) complexes with thiones. The influence of the solvent on the geometry of the complexes. , 2007, Inorganic chemistry.

[28]  L. Pellerito,et al.  Organotin(IV)n+ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects , 2002 .

[29]  J. Martins,et al.  Multinuclear 1D and 2D NMR investigations on the interaction between the pyrimidic nucleotides 5 '-CMP, 5 '-dCMP, and 5 '-UMP and diethyltin dichloride in aqueous medium , 2000 .

[30]  Jan Balzarini,et al.  Tetrameric 1:1 and monomeric 1:3 complexes of silver(I) halides with tri( p -tolyl)-phosphine: A structural and biological study , 2009 .

[31]  M. Xanthopoulou,et al.  Biological studies of organotin(IV) complexes with 2-mercaptopyrimidine , 2007 .

[32]  M. Lagunas,et al.  Synthesis of gold [Au3]3+, gold-silver [Au2Ag]3+, and gold-copper [Au2Cu]3+ loose clusters , 1993 .